GPT and mucositis: As shown in Table 5, 86.7% of patients showed at least one adverse effect (of any degree) during treatment with everolimus; 33% of patients (n = 10) showed at least one grade 3 toxicity, of which 16.7% was mucositis and 10% was liver function abnormalities (increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT) and/or gamma-glutamyl transferase (GGT)).